RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
Related Articles
Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in…
$14 million supports work to diversify human genome research | WashU Medicine
NIH renews funding for ambitious Human Pangenome Reference Sequencing Project
Mitochondria May Be a Promising Therapeutic Target for Inflammatory Diseases – News Center
Northwestern scientists have discovered how mitochondria influence the body’s immune response through modulating specific cell signaling pathways, according to a recent study published in Science…
Program
Program for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Wildfires Spare Los Angeles Area Cancer Centers—For Now
The Palisades and Eaton Fires affecting the Los Angeles, CA area have not significantly impacted cancer care or research, but patients, faculty, and staff of…
SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors
An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC.
Immune checkpoint inhibitors (ICIs) have transformed lung cancer treatment, yet their effectiveness appears restricted to certain patient subsets. Current clinical stratification based on PD-L1 expression…
Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial – The Cancer Letter
The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase…
Acalabrutinib Regimen Demonstrates Combinatorial Benefit in MCL
Tycel Phillips, MD, questioned how the regimen of acalabrutinib, bendamustine, and rituximab would compare with taking the drugs separately in mantle cell lymphoma.
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
